A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
關注allogene therapeutics的6名分析師的推薦意見
The analysis of recent analyst actions sheds light on the perception...In the last three months, 6 analysts have published ratings on Allogene Therapeutics (NASDAQ:ALLO), offering a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有6位分析師公佈了對Allogene Therapeutics（納斯達克股票代碼：ALLO）的評級，提供了從看漲到看跌的不同視角。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $11.43, a high estimate of $17.00, and a low estimate of $4.60. This current average represents a 27.89% decrease from the previous average price target of $15.85.
分析師12個月目標股價的見解已經公佈，平均目標股價爲11.43美元，最高估計爲17.00美元，低估值爲4.60美元。目前的平均價格比之前的平均目標股價15.85美元下降了27.89％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
The analysis of recent analyst actions sheds light on the perception...
對分析師最近行爲的分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。